MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
36.29
-1.74
-4.58%
After Hours: 36.29 0 0.00% 16:34 03/27 EDT
OPEN
37.72
PREV CLOSE
38.03
HIGH
38.39
LOW
36.18
VOLUME
671.95K
TURNOVER
--
52 WEEK HIGH
39.15
52 WEEK LOW
6.42
MARKET CAP
1.95B
P/E (TTM)
-18.0323
1D
5D
1M
3M
1Y
5Y
1D
Tyra Bioscience Insider Trade Sparks Fresh Buzz Around the Stock
TipRanks · 1d ago
Tyra Biosciences FY2026 director Gilla Kaplan disposes of common shares; value drops to $3,950,000
Reuters · 1d ago
Weekly Report: what happened at TYRA last week (0316-0320)?
Weekly Report · 5d ago
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance
Simply Wall St · 6d ago
Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook
Simply Wall St · 03/21 07:11
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
The Motley Fool · 03/20 16:21
Tyra Biosciences Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/20 15:45
Piper Sandler Maintains Overweight on Tyra Biosciences, Raises Price Target to $56
Benzinga · 03/20 15:35
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.